Brand | Abnova |
Product type | Primary antibodies |
Reactivity | Human,Mouse |
Host species | Rabbit |
Applications | WB,ELISA,ChIP,ChIP-Seq,Dot,IF |
Brand: | Abnova |
Reference: | PAB31324 |
Product name: | Histone H3 (K4me1) polyclonal antibody |
Product description: | Rabbit polyclonal antibody raised against synthetic peptide of Histone H3 (K4me1). |
Gene id: | 8350 |
Gene name: | HIST1H3A |
Gene alias: | H3/A|H3FA |
Gene description: | histone cluster 1, H3a |
Immunogen: | A synthetic peptide (conjugated with KLH) corresponding to Histone H3, monomethylated at lysine 4. |
Protein accession: | P68431 |
Form: | Liquid |
Recommend dilutions: | ELISA (1:400) Western Blot (1:500) ChIP (0.5-1 ug/IP) Dot Blot (1:5000) Immunofluorescence (1:200) The optimal working dilution should be determined by the end user. |
Storage buffer: | In PBS (0.05% sodium azide, 0.05% proclin 300). |
Storage instruction: | Store at -20°C. For long term storage store at -80°C. Aliquot to avoid repeated freezing and thawing. |
Note: | This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only. |
Tag: | KLH |
Product type: | Primary antibodies |
Host species: | Rabbit |
Antigen species / target species: | Human |
Reactivity: | Human,Mouse |
Application image: | |
Application image note: | ChIP assays were performed using human K562 cells. A titration consisting of 1, 2, 5 and 10 ug of antibody per ChIP experiment was analyzed. IgG (1 ug/IP) was used as a negative IP control. Quantitative PCR was performed with primers for a region surrounding the ACTB and GAS2L1 gene, respectively, used as positive controls, and for the promoters of the GAPDH and EIF4A2 genes, used as negative controls. The figure shows the recovery, expressed as a % of input (the relative amount of immunoprecipitated DNA compared to input DNA after qPCR analysis). |
Applications: | WB,ELISA,ChIP,ChIP-Seq,Dot,IF |
Shipping condition: | Dry Ice |
Publications: | Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles.Cejas P, Li L, ONeill NK, Duarte M, Rao P, Bowden M, Zhou CW, Mendiola M, Burgos E, Feliu J, Moreno-Rubio J, Guadalajara H, Moreno V, Garcia-Olmo D, Bellmunt J, Mullane S, Hirsch M, Sweeney CJ, Richardson A, Liu XS, Brown M, Shivdasani RA, Long HW. Nat Med. 2016 Jun;22(6):685-91. |